OncLive, the leading digital provider of resources and information to oncology professionals, will host its latest State of the Science Summit„¢ on non“small cell lung cancer (NSCLC) on Wednesday, Nov. 14 from 5 to 9 p.m. at the JW Marriott Orlando, Grande Lakes in Orlando, Florida. The summit will be chaired by Mark A. Socinski, M.D., executive medical director, Florida Hospital Cancer Institute.
Designed for community oncologists, fellows, nurse practitioners, nurses, physician assistants, researchers, and other health care professionals interested in the treatment of NSCLC, this summit will discuss approaches to stage IIIa and IIIb NSCLC, emerging biomarkers, updates in EGFR-positive NSCLC, updates in ALK-positive NSCLC, new data surrounding immunotherapy combinations and updates in squamous NSCLS. The event will also feature a peer exchange, followed by a panel discussion and question-and-answer session.
State of the Science Summit„¢ is a premier conference series, hosted by OncLive, that features medical experts from across the nation discussing treatment options. Each summit integrates academic and community-based physicians and health care professionals across key disciplines, from medical and surgical oncology to hematology.
Registration is free and open to all health care professionals, and food and beverages will be served. For more information and to register, visit onclive.com/meetings/soss or contact Kayla Collins at [email protected].
A digital platform of resources for practicing oncologists, OncLive offers oncology professionals information they can use to help provide the best patient care. OncLive.com is the official website for the MJH Associates, Inc., Oncology Specialty Group, which publishes OncologyLive, Oncology Nursing News and more. MJH Associates Inc. is a full-service health care communications company offering education, research and medical media, including curetoday.com and CURE magazine, the largest U.S. consumer publication focused entirely on cancer. Combining science and humanity to make cancer understandable, CURE reaches patients, cancer centers and advocacy groups.